| 
    
    	|  |  |  
        | Lancashire and South Cumbria
Formulary |  
      
        | 
              
                | Formulary Chapter 4: Central nervous system - Full Section |  
                | Useful Links |  
            |  LSCMMG: ADHD combined adult and child shared care guideline |  
            |  LSCMMG: Opioid reduction: best interests opioid reduction position statement |  
            |  LSCMMG: Opioid treatment: patient-prescriber opioid treatment agreement |  
            |  LSCMMG: Restless Legs Syndrome in Adults in Primary Care |  
				| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
 |  
	| 04.01 | Hypnotics and anxiolytics
(0,0) |  
	| 04.01.01 | Non-benzodiazepine hypnotics and sedatives 
(6,0) |  
	|  |   Benzodiazepines 
(5,0) |  
	|  |   Chloral and derivatives 
(1,0) |  
	|  |   Antihistamines 
(2,0) |  
	|  |   Alcohol
(0,0) |  
	|  |   Sodium oxybate 
(1,0) |  
	| 04.01.02 | Anxiolytics 
(2,0) |  
	|  |   Benzodiazepines 
(8,0) |  
	|  |   Beta blockers 
(1,0) |  
	|  |   Meprobamate 
(1,0) |  
	| 04.02 | Drugs used in psychoses and related disorders
(0,0) |  
	|  |   First-Generation Antipsychotic Drugs 
(10,0) |  
	|  |   Second-Generation Antipsychotic Drugs 
(9,0) |  
	| 04.02.02 | Antipsychotic depot injections 
(8,0) |  
	| 04.02.03 | Drugs used for mania and hypomania  
(1,0) |  
	|  |   Benzodiazepines 
(1,0) |  
	|  |   Antipsychotic drugs
(0,0) |  
	|  |   Carbamazepine 
(1,0) |  
	|  |   Valproic acid 
(2,0) |  
	|  |   Lithium 
(3,0) |  
	| 04.03 | Antidepressant drugs
(0,0) |  
	| 04.03.01 | Tricyclic and related antidepressant drugs
(0,0) |  
	|  |   Tricyclic antidepressants 
(8,0) |  
	|  |   Related antidepressants 
(1,0) |  
	| 04.03.02 | Monoamine-oxidase inhibitors 
(1,0) |  
	|  |   Reversible MAOIs 
(1,0) |  
	| 04.03.03 | Selective serotonin re-uptake inhibitors 
(6,0) |  
	| 04.03.04 | Other antidepressant drugs 
(6,0) |  
	| 04.03.05 | Tetracyclic antidepressants 
(2,0) |  
	| 04.04 | CNS stimulants and other drugs used for attention deficit hyperactivity disorder 
(9,0) |  
	|  |   Cocaine
(0,0) |  
	| 04.05 | Drugs used in the treatment of obesity
(0,0) |  
	| 04.05.01 | Anti-obesity drugs acting on the gastro-intestinal tract 
(5,0) |  
	| 04.05.02 | Centrally acting appetite suppressants 
(1,0) |  
	| 04.06 | Drugs used in nausea and vertigo
(0,0) |  
	|  |   Vomiting during pregnancy
(0,0) |  
	|  |   Postoperative nausea and vomiting
(0,0) |  
	|  |   Motion sickness
(0,0) |  
	|  |   Other vestibular disorders
(0,0) |  
	|  |   Cytotoxic chemotherapy 
(1,0) |  
	|  |   Palliative care
(0,0) |  
	|  |   Migraine
(0,0) |  
	|  |   Antihistamines 
(4,0) |  
	|  |   Phenothiazines and related drugs 
(3,0) |  
	|  |   Domperidone and metoclopramide 
(2,0) |  
	|  |   5HT3 antagonists 
(3,0) |  
	|  |   Neurokinin receptor antagonist 
(2,0) |  
	|  |   Hyoscine 
(1,0) |  
	|  |   Other drugs for Ménière's disease 
(1,0) |  
	| 04.07 | Analgesics 
(1,0) |  
	| 04.07.01 | Non-opioid analgesics and compound analgesic preparations 
(4,0) |  
	| 04.07.02 | Opioid analgesics 
(13,0) |  
	| 04.07.03 | Neuropathic pain 
(7,0) |  
	|  |   Trigeminal neuralgia 
(1,0) |  
	|  |   Chronic facial pain
(0,0) |  
	|  |   NMDA receptor antagonists
(0,0) |  
	| 04.07.04 | Antimigraine drugs
(0,0) |  
	| 04.07.04.01 | Treatment of the acute migraine attack
(0,0) |  
	|  |   5HT1 agonists 
(2,0) |  
	|  |   Anti-emetics
(0,0) |  
	| 04.07.04.02 | Prophylaxis of migraine 
(13,0) |  
	| 04.08 | Antiepileptics
(0,0) |  
	| 04.08.01 | Control of epilepsy 
(3,0) |  
	|  |   Partial seizures with or without secondary generalisation
(0,0) |  
	|  |   Generalised seizures
(0,0) |  
	|  |   Carbamazepine and Oxcarbazepine 
(3,0) |  
	|  |   Ethosuximide 
(1,0) |  
	|  |   Gabapentin and pregabalin 
(2,0) |  
	|  |   Lacosamide 
(2,0) |  
	|  |   Lamotrigine 
(1,0) |  
	|  |   Levetiracetam 
(2,0) |  
	|  |   Perampanel 
(1,0) |  
	|  |   Phenobarbital and other barbiturates 
(2,0) |  
	|  |   Phenytoin 
(1,0) |  
	|  |   Retigaine
(0,0) |  
	|  |   Rufinamide 
(1,0) |  
	|  |   Rufinamide
(0,0) |  
	|  |   Tiagabine 
(1,0) |  
	|  |   Topiramate 
(1,0) |  
	|  |   Valproate 
(2,0) |  
	|  |   Vigabatrin 
(1,0) |  
	|  |   Zonisamide 
(1,0) |  
	|  |   Benzodiazepines 
(1,0) |  
	|  |   Other Drugs 
(2,0) |  
	| 04.08.02 | Drugs used in status epilepticus 
(7,0) |  
	| 04.09 | Drugs used in parkinsonism and related disorders
(0,0) |  
	|  |   Dopamine receptor agonists 
(8,0) |  
	|  |   Levodopa 
(6,0) |  
	|  |   Monoamine-oxidase-B inhibitors 
(2,0) |  
	|  |   Catachol-O-methyltransferase inhibitors 
(3,0) |  
	|  |   Amantadine
(0,0) |  
	| 04.09.02 | Antimuscarinic drugs used in parkinsonism 
(5,0) |  
	| 04.09.03 | Drugs used in essential tremor, chorea, tics, and related disorders 
(5,0) |  
	|  |   Torsion dystonias and other involuntary movements 
(2,0) |  
	| 04.09.04 | Restless leg syndrome
(0,0) |  
	| 04.10 | Drugs used in substance dependence
(0,0) |  
	|  |   Alcohol dependence
(0,0) |  
	|  |   Cigarette smoking 
(1,0) |  
	| 04.10.01 | Alcohol dependence 
(2,0) |  
	| 04.10.02 | Nicotine dependence 
(2,0) |  
	| 04.10.03 | Opioid dependence 
(1,0) |  
	|  |   Opioid substitution therapy 
(3,0) |  
	|  |   Adjunctive therapy and symptomatic treatment 
(1,0) |  
	|  |   Opioid-receptor antagonists 
(1,0) |  
	| 04.11 | Drugs for dementia 
(4,0) |  
	| 04.12 | Other Nervous System medicines 
(2,0) |  |  
        |  |  |